

Effects of Hesperidin During Pregnancy on Antidepressant-like behaviour in Postpartum Mice

Ava Khodadadeh¹, Shahin Hassanpour^{2*}, Ghasem Akbari³

¹ Graduated from the Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran

² Division of Physiology, Department of Basic Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran

³ Department of Clinical Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran

Abstract

BACKGROUND: Post-partum depression is the most prevalent form of mental illness and herbal therapies are potential alternatives and adjuncts for its treatment. Hesperidin is the major flavonoid isolated from citrus fruits which has neuroprotective, antioxidant and antidepressant activity.

OBJECTIVES: We studied the effect of exposure to Hesperidin during pregnancy on postpartum antidepressant-like effects in mice.

METHODS: Twelve male and 40 female mice (28-30 gr) were randomly selected and after determination of the pregnancy using vaginal plaque, allocated into 4 experimental groups. Group 1 was kept as control and groups 2-4 were i.p. injected with 0.1, 0.5 and 1 mg/kg of hesperidin on days of 5, 8, 11, 14 and 17 of pregnancy. The control group received i.p. injection of the saline on the same days. Following postpartum, forced swimming test (FST), tail suspension test (TST) and open field tests were used to evaluate depressive-like antidepressant activity of hesperidin. At the end of the study, serum Malondialdehyde (MDA), glutathione peroxidase (GPx), superoxide dismutase (SOD) and total antioxidant capacity (TAC) were determined.

RESULTS: According to the results, administration of the different levels of the hesperidin (0.5 and 1 mg/kg) at GD 5, 8, 11, 14 and 17 significantly decreased immobility time (S) in TST and FST on postpartum mice compared to control group ($P \leq 0.05$). Pre-partum administration of hesperidin (0.1, 0.5 and 1 mg/kg) had no significant effect on OFT of control group ($P > 0.05$). Administration of the hesperidin (0.5 and 1 mg/kg) during the GD significantly decreased MDA levels on postpartum compared to control group ($P \leq 0.05$). Also, pre-partum administration of the hesperidin (0.1, 0.5 and 1 mg/kg) significantly increased SOD and GPx levels on postpartum mice compared to control group ($P \leq 0.05$).

CONCLUSIONS: These results suggested pre-partum administration of hesperidin has antidepressant and antioxidant effect in postpartum mice.

KEYWORDS: Pregnancy, Hesperidin, Antidepressant, Antioxidant, Postpartum, Mice

Correspondence

Shahin Hassanpour, Division of Physiology, Department of Basic Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran Tel: +98 (21) 44868560, Fax: +98 (21) 44868560, Email: s.hassanpour@srbiau.ac.ir

Received: 2020-02-05 Accepted: 2020-03-17

Copyright © 2020. This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.

How to Cite This Article

Khodadadeh, A., Hassanpour, S.H., & Akbari, G.H. (2020). Effects of Hesperidin During Pregnancy on Antidepressant-like behaviour in Postpartum Mice. Iranian Journal of Veterinary Medicine, 14(3), 261-272

Introduction

Depressive disorders are the most prevalent form of mental illness worldwide. Major depression is characterized by a change in psychosocial and physical impairment mood as well as lack of interest in the surroundings (Saravi *et al.*, 2016). There are growing reports on the incidence of depression in both males and females that imposes a substantial health burden on society (Gu *et al.*, 2014). The post-partum period represents profound physiological and emotional changes in mothers to ensure the well-being and nurturance of the offspring. However, several psychiatric disorders can develop in this phase (Perani and Slattery, 2014). Post-partum mood and anxiety disorders affect maternal and infant as well as developing psychiatric disorder in later life such as post-partum depression (PPD), post-partum anxiety and post-partum psychosis (Ming and Shinn-Yi, 2016). Several animal methods such as stress-based, high-fat diet-based and pup separation models are used to induce experimental PPD (Ming and Shinn-Yi, 2016). There are growing reports of new antidepressant agents to provide clinically relevant perceptions into the neuropathology that underlies the idiopathic disease state of depression (Alimohammadi *et al.*, 2019).

Hesperidin is the major flavonoid isolated from citrus fruits (Li and Schluesener, 2017). The hesperidin molecule is composed of a glycone unit known as hesperetin and a disaccharide, rutinose (Iranshahi *et al.*, 2015). Hesperidin has several biological effects including antioxidant, anti-inflammatory, antimicrobial, anti-carcinogenic and anti-allergic effects and insulin-sensitizing activity (Li and Schluesener, 2017). In addition, hesperidin neuropharmacological properties have been reported for the hesperidin (Ha-

jalyani *et al.*, 2019). It has high potential for radical scavenging and protective effects and can cross blood brain barrier (Khan and Parvez, 2015). Hesperidin promotes neuronal survival, differentiation and neuroprotective capacity of astrocytes (Matias *et al.*, 2017) which have positive effect for stroke, Huntington's, Alzheimer's and Parkinson's disease (Antunes *et al.*, 2014). Several antioxidant compounds, such as flavonoids derived from natural products, have demonstrated neuroprotective activity in PPD (Antunes *et al.*, 2014).

Antioxidant enzymes, such as glutathione peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD), also are important mediators in the reduction of oxidative stress (Khan *et al.* 2012). It is reported that (50 mg/kg) treatment increased GPx, SOD and CAT activity in mouse model of Parkinson's disease (Antunes *et al.*, 2014). Hesperidin in the acute (1 mg/kg) and chronic (0.1, 0.3 and 1 mg/kg) levels improved tail suspension test (TST) which improved antidepressant-like effect (Donato *et al.*, 2014). Based on the aforementioned evidence, we sought to investigate effects of the Hesperidin exposure during pregnancy on antidepressant-like effects postpartum in mice.

Materials and methods

Animals

The NMRI male (n=12) and virgin female mice (n=40, age: 8–10 weeks old and 28–30 gr) were supplied from the Razi Serum and Vaccine Institute (Tehran, Iran). The animals were kept five mice/cage in standard plastic cages at laboratory conditions (temperature of 22 ± 2 °C and 12/h light/dark cycle) with *ad libitum* access to standard chow pellet (Pars Dam Co, Tehran, Iran) and fresh wa-

ter. The animals acclimatized for 1 week before beginning the study. All experimental procedures were approved by the Animal Ethics Committee of Science and Research Branch of Islamic Azad University, Tehran, Iran (IR.IAU.SRB.REC.1398.117) following the Guidelines for the Care and Use of Laboratory Animals in Research. After 1 week of acclimatization, the female mice were caged with fertile male mice. Each morning, the female mice were examined for the presence of sperm or vaginal plug. Presence of the vaginal plug or sperm was defined as onset of pregnancy. The pregnant mice were randomly assigned into 4 groups ($n = 10$ for each group) and provided *ad libitum* food and water.

Drugs

Hesperidin (H5254) was purchased from Sigma Aldrich, (Saint Luis, USA) and were dissolved by the sequential addition of dimethyl sulfoxide up to a final concentration of 5%, a water solution of 0.25% Tween 80 up to a final concentration of 20% and saline to complete 100% volume (Donato *et al.*, 2014).

Experimental procedure

In control group, pregnant mice were i.p. injected with saline containing 0.05% Tween-80 at gestation day (GD) 5, 8, 11, 14 and 17. In groups 2, 3 and 4, mice were injected with 0.1, 0.5 and 1 mg/kg of hesperidin at GD 5, 8, 11, 14 and 17, respectively. The dosage of the hesperidin was determined based on the previous reports (Antunes *et al.*, 2014; Donato *et al.*, 2014; Khan and Parvez, 2015; Pari *et al.*, 2015) and our pilot study. Then after delivery, antidepressant-like effects of the hesperidin were evaluated using neurobehavioral tests that were done on female mice.

Tail suspension test (TST)

The TST is one of the most common techniques for assessing antidepressant-like ac-

tivity in mice (Cryan *et al.*, 2005). The TST was done based on the method stated by Steru *et al.* (1985). Briefly, the mice were far from nearest objects and were both acoustically and visually isolated from observing or interacting each other. Each mouse was then suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the extremity of the tail, in such a position that it cannot escape or hold on to nearby surfaces. Immobility time was recorded during a 6 min period. Mice were considered immobile only when they had no strong body shaking and movement of the limbs as they hung passively and completely motionless.

Open field test (OFT)

The Open field test (OFT) was used to determine possible effects of hesperidin on the locomotor and exploratory activities. The OFT was done using 45×45×30 cm³ poly wood cage. The floor of OFT cage was divided by masking tape markers into 3×3 squares. Each animal was placed individually at the center of the apparatus and observed for 6 min to record the locomotion (number of segments crossed with the four paws) (Donato *et al.*, 2014).

Forced Swimming Test (FST)

FST was carried out following the protocol as described previously in mice (Castagné *et al.*, 2011). Each mouse was plunged into a glass cylinder (height: 25 cm; diameter: 15 cm) containing 10 cm of water (25 ± 1 °C) for 15 min (pre-test session). Twenty-four hours later, the mouse was placed in the cylinder again and left for a 6 min period (test session). The immobility time for mouse was described as when it ceased struggling and remained floating motionless in the water, making only small movements necessary to keep its head above water. The total duration of immobility during the last 4 min of the 6

min testing period was measured.

Antioxidant activity

At the end of the neurobehavioral tests, blood samples were taken from each mouse and serum Malondialdehyde (MDA), SOD, GPx and total antioxidant capacity (TAC) were determined using Zell Bio GmbH (Germany) assay kits (ZB-MDA-48A, ZB-SOD-A48, ZB-GPX-A48 and ZB-TAC-48A, respectively).

Statistical analysis

Data was analyzed by one-way analysis of variance (ANOVA) and is presented as the mean \pm SEM. For treatments found to have an effect according to the ANOVA, mean

values were compared with Tukey's test. $P \leq 0.05$ was considered to indicate significant differences between the treatments.

Results

Effect of exposure to different levels of Hesperidin during pregnancy on immobility time (S) in TST on postpartum mice is presented in Figure 1. As seen, administration of the different levels of the hesperidin (0.5 and 1 mg/kg) at GD 5, 8, 11, 14 and 17 significantly decreased immobility time (s) in TST on postpartum mice compared to control group ($P \leq 0.05$).




Figure 1. Effect of exposure to different levels of Hesperidin during pregnancy on immobility time (sec) in TST on postpartum mice. TST: tail suspension test. There are significant differences between groups with different superscripts (a, b and c; $P \leq 0.05$).

According to the Figure 2, administration of the hesperidin (0.5 and 1 mg/kg) at GD 5, 8, 11, 14 and 17 significantly

decreased immobility time (S) in FST on postpartum mice compared to control group ($P \leq 0.05$).




Figure 2. Effect of exposure to different levels of Hesperidin during pregnancy on immobility time (sec) in FST on postpartum mice. FST: forced swimming test. There are significant differences between groups with different superscripts (a, b and c; $P \leq 0.05$).

However, pre-partum exposure to the hesperidin (0.1, 0.5 and 1 mg/kg) had no signif-

icant effect on OFT following delivery compared to control group ($P>0.05$) (Figure 3).




Figure 3. Effect of exposure to different levels of Hesperidin during pregnancy on immobility time (S) in OFT on postpartum mice. OFT: open field test.

As seen in Figure 4, administration of the hesperidin (0.5 and 1 mg/kg) during the GD significantly decreased MDA levels on postpartum mice compared to control group

($P\leq 0.05$). Furthermore, administration of the hesperidin (0.5 and 1 mg/kg) significantly increased GPx levels on postpartum mice compared to control group ($P\leq 0.05$) (Figure 5).




Figure 4. Effect of exposure to different levels of Hesperidin during pregnancy on postpartum serum Malondialdehyde (MDA) level in mice. There are significant differences between groups with different superscripts (a and b; $P\leq 0.05$).




Figure 5. Effect of exposure to different levels of Hesperidin during pregnancy on postpartum serum glutathione peroxidase (GPx) level in mice. There are significant differences between groups with different superscripts (a and b; $P\leq 0.05$).

Pre-partum exposure to the hesperidin (0.1, 0.5 and 1 mg/kg) significantly increased SOD levels on postpartum mice compared to control

group ($P \leq 0.05$) (Figure 6) but had no significant effect on TAC following delivery compared to control group ($P > 0.05$) (Figure 7).




Figure 6. Effect of exposure to different levels of Hesperidin during pregnancy on postpartum serum superoxide dismutase (SOD) level in mice. There are significant differences between groups with different superscripts (a and b; $P \leq 0.05$).




Figure 7. Effect of exposure to different levels of Hesperidin during pregnancy on postpartum serum total antioxidant capacity (TAC) in mice.

Discussion

Depression is a common, chronic, recurrent illness with severe morbidity. Although a number of research studies have been done on its physiological mechanisms, brain areas underlying this disorder are not yet well understood. Postpartum depression is a severe mood disorder which happens right away after childbirth and is observed by sadness and anxiety in mothers (O'Hara and McCabe, 2013). According to the results, administration of the different doses of hesperidin (0.5 and 1 mg/kg) at GD 5, 8, 11, 14 and 17 significantly decreased immobility time in TST and FST on

postpartum mice compared to control group. Hesperidin (1mg/kg) significantly reduced immobility time in FST in mice (Filho *et al.*, 2013). In a similar study, it was reported hesperidin (50 mg/kg) improved depressive-like behavior in the TST and memory in the Morris water maze test (Antunes *et al.*, 2014). The antidepressant-like effect of hesperidin has been reported in FST and TST tests (Souza *et al.*, 2013). Moreover, hesperidin suppressed depressive-like behaviors in TST using intra-striatal injection of 6-hydroxydopamine in Parkinson's disease (Antunes *et al.*, 2014). Hesperidin (25, 50 and 100 mg/kg) had anti-depressant effect in diabetic rats (El-Mara-

sy *et al.*, 2014), our results were in agreement with the reports.

Immobility time in FST resembles a state of despair and mental depression. Stress-induced depression like behavioral alterations are routinely determined by TST and FST in rodents. Immobility time in TST and FST reflects the behavioral despair which is similar to depression in human (Walia and Gilhotra, 2016). Differences on neurochemical pathways of the FST and TST induced performance are reported/have been reported. At face value, these two tests appear very similar but this potency difference appears due to both pharmacokinetic and pharmacodynamic factors (Amin *et al.*, 2015). We also studied effect of the hesperidin on locomotor activity using open field test. AS observed, pre-partum exposure to the hesperidin (0.1, 0.5 and 1 mg/kg) had no significant effect on OFT following delivery. It is revealed hesperidin at the levels of 0.1, 0.5 and 1 mg/kg, had no sedative effect, our finding was similar to this report.

Bioavailability is a key step in ensuring the bio efficacy of hesperidin which is affected by physiological conditions. It is selectively metabolized by both cytochrome P450 isoforms (CYP1A and CYP1B1) to eriodictyol, indicating that there is O-demethylation of hesperidin in liver. It has higher bio activity compared to the other flavonoids which can be related to the inhibition of phase II metabolism (glucuronidation and sulfation of hesperidin). The metabolites of hesperidin are detected in urine but not in feces. In oral administration, more than 40% of the radioactivity of hesperidin-³-¹⁴C was expired as carbon dioxide which indicates further bacterial degradation in the colon than blood circulation (Roohbakhsh *et al.*, 2014). The ability of hesperidin to cross the blood brain barrier makes it an ideal bio-

active substance for treatment of CNS disorders (Iranshahi *et al.*, 2015). Hesperidin decreases risk of Parkinson's disease as well as Alzheimer's disease in flavonoid deficient patient (Antunes *et al.*, 2014). The neuroprotective role of the hesperidin is mediated via anti-inflammatory and antioxidant activities (Menze *et al.*, 2012). Hesperidin (0.01, 0.3 and 1 mg/kg) has antidepressant-like effect in TST and decreased nitrate/nitrite as well as increased hippocampal brain-derived neurotrophic factor (BDNF) in the hippocampus of mice (Donato *et al.*, 2014). Based on literature, NO/cGMP pathway has a key role on antidepressant effect of hesperidin (Donato *et al.*, 2014). It is reported that nitrate/nitrite levels decreased in the hippocampus of hesperidin-treated mice. Anti-depressant activity of the hesperidin is inhibited by pretreatment with L-arginine (processor of nitric oxide). Also, administration of the hesperidin increased the brain-derived neurotrophic factor (BDNF) level in the hippocampus of mice (Donato *et al.*, 2014). Perhaps, antidepressant-like activity of the flavonoids mediates via BDNF (Hajialyani *et al.*, 2019). Also, it is reported antidepressant effect of hesperidin is also dependent on nitric oxide (NO)/cGMP pathway (Donato *et al.*, 2014). Hesperidin, acute (1 mg/kg) and chronic (0.1, 0.3 and 1 mg/kg), reduced nitrate/nitrite levels in the hippocampus of mice (Donato *et al.* 2014). However, the mechanisms and brain areas underlying the pathophysiology of depression are not fully elicited. It is suggested plasma nitrate levels and nitric oxide synthase (NOS) expression increased in the hippocampus of depressed patients. Inhibition of NOS may decrease immobility time in the TST elicited by hesperidin (Donato *et al.*, 2014). Based on the limitation of the study, we were not able to determine interaction of the hesperi-

din with NO pathway.

Based on the findings, pre-partum exposure to the hesperidin (0.1, 0.5 and 1 mg/kg) significantly increased SOD and GPx levels on post-partum mice compared to control group. It is reported that hesperidin has antioxidant protection against free radicals-induced oxidative damage and photo-damage repair enhancer (Hemant Kumar *et al.*, 2017). However, Antunes *et al.* (2014) reported hesperidin (50 mg/kg) treatment attenuated the 6-OHDA-induced reduction in GPx, SOD and CAT levels in mouse model of Parkinson's disease. Also, it is reported hesperidin increased glutathione, SOD, CAT and decreased MDA and nitrite level (Roohbakhsh *et al.*, 2014). Administration of hesperidin (20, 40 and 80 mg/kg) reversed the levels of serum hepatic CAT, SOD, GPx and glutathione S-transferase (GST) enzyme levels (Pari *et al.*, 2015) which is similar to our result. New findings revealed the antioxidant activity of hesperidin mediates by radical scavenging activity and ERK/Nrf2 signaling pathway as well (Elavarasan *et al.*, 2012). Injection of the hesperidin (0.5 and 1 mg/kg) during the GD significantly decreased MDA levels on postpartum mice compared to control group. Hesperidin has protective effect against reactive oxygen species (ROS) production and oxidative stress. Hesperidin enhanced antioxidant enzymes CAT, SOD and GST level (Visnagri *et al.*, 2014). The enzymatic antioxidants CAT, SOD, GPx and GST have crucial role on scavenging ROS. Hesperidin has protective effect against oxidative damage due to the ability of enhanced antioxidant activity. There is a correlation between depressive disorders and increased oxidative stress, neuro-inflammation and diminished anti-oxidant defenses (Black *et al.*, 2014). The positive effect of the antioxidant effects of antidepressants in the treatment of

major depressive disorder is well documented (Da Silva *et al.*, 2014).

Hesperidin-therapy is safe, has a non-accumulative nature with lowest adverse effect, even during the pregnancy period (Hajialyani *et al.*, 2019). Hesperidin administered at doses up to 5% for 13 weeks had no mutagenic, toxic, and carcinogenic effects on mice (Garg *et al.*, 2001). In the model of rat colon carcinogenesis, hesperidin decreased intestinal tumor incidents via antioxidant defense with no toxicity to the liver and colon (Aranganathan and Nalini, 2009). Hesperidin is able to decrease streptozotocin-isoproterenol-induced myocardial toxicity (Agrawal *et al.*, 2014). Although hesperidin is a safe phytochemical, possible interactions of this phytochemical should be considered (Hajialyani *et al.*, 2019). In view of our findings, the obtained data indicate hesperidin has protective activity against postpartum depression. However, further research is needed to clarify the precise molecular mechanisms involved in the antidepressant effects of the hesperidin.

Acknowledgments

The authors thank the Faculty of Veterinary Medicine, Science and Research Branch, Tehran, Iran for their cooperation. This research was conducted as a part of the DVM thesis of the first author.

Conflicts of interest

The authors declared that there are no conflicts of interest.

References

- Agrawal, Y.O., Sharma, P.K., Shrivastava, B., Arya, D.S., Goyal, S.N. (2014) Hesperidin blunts streptozotocin-isoproterenol induced myocardial toxicity in rats by altering of PPAR-gamma receptor. *Chem Biol Interact*, 19, 211–220. <https://doi.org/10.1016/j.cbi.2014.06.010> PMID: 24954035

- Alimohammadi, S., Hosseini, M.S., Behbood, L. (2019) Prenatal exposure to zinc oxide nanoparticles can induce depressive-like behaviors in mice offspring. *Int J Peptide Res Ther*, 25(1), 401–409. [https://doi.org/ 10.1007/s10989-018-9686-9](https://doi.org/10.1007/s10989-018-9686-9)
- Amin, B., Nakhsaz, A., Hosseinzadeh, H. (2015) Evaluation of the antidepressant-like effects of acute and sub-acute administration of crocin and crocetin in mice. *Avicenna J Phytomed*, 5 (5), 458-468. PMID:26468466
- Antunes, M.S., Goes, A.T., Boeira, S.P., Prigol, M., Jesse, C.R. (2014) Protective effect of hesperidin in a model of Parkinson's disease induced by 6-hydroxydopamine in aged mice. *Nutrition*, 104, 19–26. [https://doi.org/ 10.1016/j.nut.2014.03.024](https://doi.org/10.1016/j.nut.2014.03.024) PMID: 25280422
- Aranganathan, S., Nalini N. (2009) Efficacy of the potential chemopreventive agent, hesperetin (citrus flavanone), on 1,2-dimethylhydrazine induced colon carcinogenesis. *Food Chem Toxicol*, 47, 2594–2600. [https://doi.org/ 10.1016/j.fct.2009.07.019](https://doi.org/10.1016/j.fct.2009.07.019) PMID: 19632289
- Black, C.N., Bot, M., Scheffer, P.G., Cuijpers, P., Penninx, B.W. (2014) Is depression associated with increased oxidative stress? A systematic review and meta-analysis. *Psychoneuroendocrinology*, 51c, 164-175. [https://doi.org/ 10.1016/j.psyneuen.2014.09.025](https://doi.org/10.1016/j.psyneuen.2014.09.025) PMID: 25462890
- Castagné, V., Moser, P., Roux, S., Porsolt, R.D. (2011) Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. *Curr Protoc Neurosci*, <https://doi.org/10.1002/0471142301.ns0810as55> PMID:21462162
- Cryan, J.F., Mombereau, C., Vassout, A. (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. *Neurosci Biobehav Rev*, 29(4–5), 571–625. [https://doi.org/ 10.1016/j.neubiorev.2005.03.009](https://doi.org/10.1016/j.neubiorev.2005.03.009) PMID: 15890404
- Da Silva, A.I., Monteiro Galindo, L.C., Nascimento, L., Moura Freitas, C., Lagranha, C.J., Lopes de Souza, S. (2014) Fluoxetine treatment of rat neonates significantly reduces oxidative stress in the hippocampus and in behavioral indicators of anxiety later in postnatal life. *Can J Physiol Pharmacol*, 92, 330-337. [https://doi.org/ 10.1139/cjpp-2013-0321](https://doi.org/10.1139/cjpp-2013-0321) PMID: 24708216
- Donato, F., de Gomes, M.G., Goes, A.T., Filho, C.B., Del Fabbro, L., Antunes, M.S., et al. (2014) Hesperidin exerts antidepressant-like effects in acute and chronic treatments in mice: possible role of l-arginine-NOCGMP pathway and BDNF levels. *Brain Res Bull*, 104, 19–26. [https://doi.org/ 10.1016/j.brainresbull.2014.03.004](https://doi.org/10.1016/j.brainresbull.2014.03.004) PMID: 24709058
- El-Marasy, S.A., Abdallah, H.M.I., El-Shenawy, S.M., El-Khatib, A.S., El-Shabrawy, O.A., Kenawy, S.A. (2014) Anti-depressant effect of hesperidin in diabetic rats. *Can J Physiol Pharmacol*, 92, 945–952. [https://doi.org/ 10.1139/cjpp-2014-0281](https://doi.org/10.1139/cjpp-2014-0281) PMID: 25358020
- Filho, C.B., Souza, L.C., de Gomes, M.C. et al. (2013) Kappa-opioid receptors mediate the antidepressant-like activity of hesperidin in the mouse forced swimming test. *Eur J Pharmacol*, 698(1-3), 286–291. [https://doi.org/ 10.1016/j.ejphar.2012.11.003](https://doi.org/10.1016/j.ejphar.2012.11.003) PMID: 23178563
- Garg, A., Garg, S., Zaneveld, L., Singla, A. (2001) Chemistry and pharmacology of the citrus bioflavonoid hesperidin. *Phytother Res*, 15, 655–669. [https://doi.org/ 10.1002/ptr.1074](https://doi.org/10.1002/ptr.1074) PMID: 11746857
- Gu, X., Zhou, Y., Wu, X., Wang, F., Zhang, C.Y., Du, C., Shen, L., Chen, X., Shi, J., Liu, C., Ke, K. (2014) Antidepressant-like effects of auraptenol in mice. *Sci Rep*, 4, 4433. [https://doi.org/ 10.1038/srep04433](https://doi.org/10.1038/srep04433) PMID: 24658501
- Hajialyani, M., Farzaei, M.H., Echeverría, J., Nabavi, S.M., Uriarte, E., Sobarzo-Sánchez, E. (2019) Hesperidin as a neuroprotective agent: A review of animal and clinical evidence. *Molecules*, 24, 648. <https://doi.org/10.3390/molecules24030648> PMID:30759833
- Hemanth kumar, B., Dinesh kumar, B., Diwan, P.V. (2017) Hesperidin, a citrus flavonoid, protects against l-methionine-induced hyperhomocysteinemia by abrogation of oxidative stress, endothelial dysfunction and neurotoxicity in Wistar rats. *Pharm Biol*, 55, 146-155. [https://doi.org/ 10.1080/13880209.2016.1231695](https://doi.org/10.1080/13880209.2016.1231695) PMID: 27677544
- Iranshahi, M., Rezaee, R., Parhiz, H., Roohbakhsh, A., Soltani, F. (2015) Protective effects of flavonoids against microbes and toxins: The cases of hesperidin and hesperetin. *Life Sci*, 137, 125–132. [https://doi.org/ 10.1016/j.lfs.2015.07.014](https://doi.org/10.1016/j.lfs.2015.07.014) PMID: 26188593

- Khan, M.H.A., Parvez, S. (2015) Hesperidin ameliorates heavy metal induced toxicity mediated by oxidative stress in brain of Wistar rats. *J Trace Elem Med Biol*, 31, 53-60. <https://doi.org/10.1016/j.jtemb.2015.03.002> PMID: 26004892
- Khan, M.M., Raza, S.S., Javed, H., Ahmad, A., Khan, A., Islam, F., et al. (2012) Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease. *Neurotox Res*, 22,1-15. <https://doi.org/10.1007/s12640-011-9295-2> PMID: 22194158
- Li, C. Schluesener, H. (2017) Health-promoting effects of the citrus flavanone hesperidin. *Crit Rev Food Sci Nutr*, 57, 613-631. <https://doi.org/10.1080/10408398.2014.906382> PMID: 25675136
- Matias, I., Diniz, L.P., Buosi, A., Neves, G., Stipursky, J., Gomes, F.C.A. (2017) Flavonoid hesperidin induces synapse formation and improves memory performance through the astrocytic TGF- β 1. *Front. Aging Neurosci*, 9,184. <https://doi.org/10.3389/fnagi.2017.00184> PMID: 28659786
- Menze, E.T., Tadros, M.G., Abdel-Tawab, A.M., Khalifa, A.E. (2012) Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats. *Neurotoxicology*, 33,1265-75. <https://doi.org/10.1016/j.neuro.2012.07.007> PMID: 22850463
- Ming, L.I., Shinn-Yi, C. (2016) Modeling postpartum depression in rats: theoretic and methodological issues. *Zool Res*, 37(4), 229-236. <https://doi.org/10.13918/j.issn.2095-8137.2016.4.229> PMID: 27469254
- O'Hara, M.W., McCabe, J.E. (2013) Postpartum depression: current status and future directions. *Ann Rev Clin Psychol*, 9 (1), 379- 407. <https://doi.org/10.1146/annurev-clinpsy-050212-185612> PMID: 23394227
- Pari, L., Karthikeyan, A., Karthika, P., Rathinam, A. (2015) Protective effects of hesperidin on oxidative stress, dyslipidaemia and histological changes in iron-induced hepatic and renal toxicity in rats. *Toxicol Rep*, 2: 46-55. <https://doi.org/10.1016/j.toxrep.2014.11.003> PMID: 28962336
- Perani, C.V., Slattery, D.A. (2014) Using animal models to study post-partum psychiatric disorders. *Br J Pharmacol*, 171(20), 4539-4555. <https://doi.org/10.1111/bph.12640> PMID: 24527704
- Roohbakhsh, A., Parhiz, H., Soltani, F., Rezaee, R., Iranshahi, M. (2014) Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin — A mini-review. *Life Sci*, 113,1-6. <https://doi.org/10.1016/j.lfs.2014.07.029> PMID: 25109791
- Saravi, S.S.S., Arefidoust, A., Yaftian, R., Saravi, S.S.S., Dehpour, A.R. (2016) 17 alpha-ethinyl estradiol attenuates depressive-like behavior through GABA(A) receptor activation/nitric pathway blockade in ovariectomized mice. *Psychopharmacology*, 233, 1467-1485. <https://doi.org/10.1007/s00213-016-4242-9> PMID: 26883875
- Souza, L.C., de Gomes, M.G., Goes, A.T., Del Fabbro, L., Carlos Filho, B., Boeira, S.P., Jesse, C.R. (2013) Evidence for the involvement of the serotonergic 5-HT 1A receptors in the antidepressant-like effect caused by hesperidin in mice. *Prog Neuropsychopharmacol*, 40, 103-109. <https://doi.org/10.1016/j.pnpbp.2012.09.003> PMID: 22996046
- Steru, L., Chermat, R., Thierry, B., Simon, P. (1985) The tail suspension test: a new method for screening antidepressants in mice. *Psychopharmacology*, 85(3),367-370. <https://doi.org/10.1007/bf00428203> PMID: 3923523
- Visnagri, A., Kandhare, A.D., Chakravarty, S., Ghosh, P., Bodhankar, S.L. (2014) Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions. *Pharm Biol*, 52,814-28. <https://doi.org/10.3109/13880209.2013.870584> PMID: 24559476
- Walia, V., Gilhotra, N. (2016) Nitriergic influence in the compromised antidepressant effect of fluoxetine in stressed mice. *J Appl Pharm Sci*, 6 (10),092-097. <https://doi.org/10.7324/JAPS.2016.601012>

اثرات هیسپیریدين طی آبستنی بر رفتار ضدافسردگی پس از زایمان در موش سوری

آوا خداداده^۱، شاهین حسن پور^۲، قاسم اکبری^۳

^۱ دانش آموخته دکتری عمومی دامپزشکی، دانشکده دامپزشکی، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران
^۲ بخش فیزیولوژی، گروه علوم پایه، دانشکده دامپزشکی، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران
^۳ گروه علوم درمانگاهی، دانشکده دامپزشکی، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران

(دریافت مقاله: ۱۶ بهمن ماه ۱۳۹۸، پذیرش نهایی: ۱۷ اسفند ماه ۱۳۹۸)

چکیده

زمینه مطالعه: افسردگی پس از زایمان یکی از شایع‌ترین بیماری‌های روان می‌باشد و درمان گیاهی جایگزین مناسبی برای درمان آن می‌باشد. هیسپیریدين مهمترین فلاونوئید استخراج شده از مرکبات می‌باشد که اثرات محافظتی بر نورون، آنتی اکسیدانی و ضد افسردگی دارد.

هدف: مطالعه حاضر به منظور بررسی اثرات قرار گرفتن در معرض هیسپیریدين در دوران آبستنی بر اثرات ضدافسردگی متعاقب زایمان در موش‌های سوری انجام گرفت.

روش کار: ۱۲ موش سوری نر و ۴۰ موش ماده بالغ (۲۸-۳۰ گرم) بطور تصادفی در کنار یکدیگر نگهداری شده و پس از تایید آبستنی بوسیله پلاک واژن، به چهار گروه تقسیم شدند. گروه اول بعنوان کنترل و گروه ۲، ۳ و ۴ به ترتیب تزریق ۰/۱، ۰/۵ و ۱ گرم بر کیلوگرم هیسپیریدين را طی روزهای ۵، ۸، ۱۱، ۱۴ و ۱۷ آبستنی را بصورت تزریق داخل صفاقی دریافت کردند. به گروه کنترل نیز در همان فواصل سرم فیزیولوژی تزریق شد. پس از زایمان ارزیابی اثرات ضدافسردگی هیسپیریدين با استفاده از آزمون‌های شنای اجباری، تعلیق دم و اوپن فیلد انجام گرفت. در انتهای مطالعه، نمونه خون اخذ و مقادیر سرمی مالون دی آلدئید (MDA)، گلووتاتیون پراکسیداز (GPx)، سوپراکسید دیسموتاز (SOD) و ظرفیت آنتی اکسیدانی تام (TAC) ارزیابی شد.

نتایج: باتوجه به نتایج بدست آمده تجویز هیسپیریدين (۰/۱، ۰/۵ و ۱ گرم بر کیلوگرم) طی روزهای ۵، ۸، ۱۱، ۱۴ و ۱۷ آبستنی بطور معنی داری موجب کاهش زمان بی‌حرکی (ثانیه) در تست‌های شنای اجباری و تعلیق دم متعاقب زایمان در مقایسه با گروه کنترل شد ($P \leq 0/05$). تجویز هیسپیریدين (۰/۱، ۰/۵ و ۱ گرم بر کیلوگرم) طی روزهای ۵، ۸، ۱۱، ۱۴ و ۱۷ آبستنی بطور اثر معنی داری در تست اپن فیلد در مقایسه با گروه کنترل نداشت ($P > 0/05$). تجویز هیسپیریدين (۰/۱، ۰/۵ و ۱ گرم بر کیلوگرم) طی آبستنی موجب کاهش مالون دی آلدئید متعاقب زایمان در مقایسه با گروه کنترل شد ($P \leq 0/05$). همچنین، تجویز هیسپیریدين (۰/۱، ۰/۵ و ۱ گرم بر کیلوگرم) در دوران آبستنی موجب افزایش گلووتاتیون پراکسیداز و سوپراکسید دیسموتاز در مقایسه با گروه کنترل شد ($P \leq 0/05$).

نتیجه گیری نهایی: نتایج نشان داد که قرار گرفتن در معرض هیسپیریدين در دوران آبستنی اثرات ضدافسردگی و آنتی اکسیدانی متعاقب زایمان در موش سوری دارد.

واژه‌های کلیدی:

آبستنی، هیسپیریدين، ضدافسردگی، آنتی اکسیدان، زایمان، موش.